Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

Top Infectious Disease News of the Week—May 6, 2018

MAY 11, 2018 | CONTAGION® EDITORIAL STAFF

#5: National Cancer Institute Analysis Reveals New Cancer Risks Among Adults With HIV

New antiretroviral therapies (ART) mean patients are living with HIV—and living longer.

However, even as improved screening and risk-management approaches slowly reduce the incidence of cancer among those who are HIV-positive, various forms of the disease will continue to be a significant concern, at least according to the findings of an analysis performed by researchers at the National Cancer Institute (NCI) and published on May 8th by the journal Annals of Internal Medicine.

Indeed, their work suggests that cancers not previously associated with HIV/AIDS—so-called non-AIDS-defining cancers—such as prostate and lung cancers will be the most common cancers among those “aging with HIV” by 2030.

Read more about cancer risks among adults with HIV.

#4: Significant Enrollment Milestone Met in Phase 3 Trial of Novavax’s RSV Vaccine

Novavax, a clinical-stage biotechnology company, has just announced that it has reached a significant enrollment milestone for their clinical phase 3 trial, dubbed Prepare, regarding their vaccine candidate for the prevention of respiratory syncytial virus (RSV) in infants via maternal immunization.

A total of 4,600 healthy, pregnant women in their third trimester have been enrolled in the global Prepare trial, which was first initiated in December 2015; to date, at least 3,000 of participants have received the RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine).

Read more about Novavax’s RSV vaccine.

Want more information on this topic and the opportunity to ask questions of an expert? Register for a live, ACPE accredited webinar February 28th 8-9 PM EST at this link: https://www.pharmacytimes.org/live-events/1106
FEATURED
Big advances in treatment can